NGS analysis of germline mutation profile of patients with hepatocellular carcinoma in China.

Authors

null

Xiaobing Wu

Eastern Hepatobiliary Surgery Hospital, Shanghai, China

Xiaobing Wu , Didi Guo , Tiantian Han , Yaping Zhao , Juan Ma , Guanghua Lu , Fanfeng Bu , Siqi Chen , Wanglong Deng , Ran Ding

Organizations

Eastern Hepatobiliary Surgery Hospital, Shanghai, China, The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd, The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China, The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China, Jiangsu Simcere Diagnostics Co., Nanjing, China, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China

Research Funding

No funding received

Background: Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death worldwide with very poor prognosis. Many studies have focused on oncogene characteristics, however, the germline landscape of Chinese HCC patients has not been fully clarified. The purpose of this study is to assess the inherited genetic factors regarding germline mutations in Chinese HCC patients. Methods: Genetic mutations were reviewed in 1670 Chinese HCC patients who underwent hybridization capture based next-generation sequencing (NGS). The pathogenicity of germline mutations was categorized based on American College of Medical Genetics and Genomics (ACMG) guidelines. Results: Of 1670 patients with HCC, 110 (6.7%) patients were identified to carry 111 pathogenic variants(P) or likely pathogenic variants(LP) in 112-cancer predisposition gene panel, and there was no age difference between P/LP group and non-P/LP group (average age: 57 vs 56, p = 0.64). The most frequently germline mutated genes were BRCA1/2 (11.7%), followed by ATM(4.5%), BLM(4.5%), ERCC2(4.5%), ERCC3(4.5%) and BRIP1(3.6%), ERCC4(3.6%), FANCD2(3.6%), MUTYH(3.6%), RAD50(3.6%). Of all the 111 germline mutations, 47% (n = 52) lay in the Homologous Recombination Repair (HRR) pathways. Both in P/LP group and non-P/LP group, the most frequently somatic mutated genes were TP53, TERT and MUC16. 7/110(6.4%)of patients in P/LP group were high TMB(≥10 mutations/megabase) and 131/1560(8.5%) in non-P/LP group. There was no statistical difference in TMB between P/LP and non-P/LP group. Conclusions: Taken together, we have presented the spectrum of pathogenic germline mutations in Chinese HCC patients. P/LP germline variants in cancer predisposition genes were detected in 6.7% of those patients, and predisposition genes associated with HCC risk needs further investigation. Inherited genetics should not be overlooked in HCC as there are important implications for precision treatment, future risk of cancers, and familial cancer risk.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Prevention, Risk Reduction, and Hereditary Cancer

Track

Prevention, Risk Reduction, and Genetics

Sub Track

Germline Genetic Testing

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 10585)

DOI

10.1200/JCO.2022.40.16_suppl.10585

Abstract #

10585

Poster Bd #

460

Abstract Disclosures

Similar Abstracts

First Author: Darren Cowzer

Abstract

2019 ASCO Annual Meeting

MUC16 germline mutations may predispose inherited cancer family members to lung adenocarcinomas.

First Author: Tao Wang

Abstract

2023 ASCO Gastrointestinal Cancers Symposium

Responses to first-line systemic therapies in patients with hepatocellular carcinoma with TERT promoter mutations.

First Author: Jeremy Chang